Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.
ARS Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Detailed revenue, profitability, cash position and operating updates in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $37.7M, up from $32.5M, with neffy U.S. product revenue $33.4M
- U.S. neffy market share reached 5%, while field-targeted accounts reached 9% versus 2% in non-targeted accounts
- SG&A fell 42% from the first-half 2026 quarterly average, supporting the year-end 2027 cash-flow breakeven target
- Cash, cash equivalents and short-term investments totaled $138.4M, while Q3 net loss narrowed to $35.6M from $51.2M
- ARS-2 Phase 2b interim CSU data expected in Q1 2027, creating a near-term clinical catalyst beyond anaphylaxis
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARS Pharmaceuticals, Inc. 8-K filings
Get the next SPRY 8-K as it lands
Follow SPRY for push alerts, or ask the research agent what this filing means.